Dupilumab for Keloid

Phase-Based Progress Estimates
KeloidDupilumab - Drug
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial looks at whether the medication dupilumab is effective and safe in treating keloids.

Treatment Effectiveness

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Assessed at Screening, weeks 0, 4, 8, 12, 16, 20, 24

Week 0
Baseline and Week 24
Dermatology Life Quality Index (DLQI).
Number of patients with keloid volume and size improvement
Patient and Observer Scar Assessment Scale (POSAS)
Vancouver Scar Scale (VSS).

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

OLE Period: Dupilumab/Dupilumab
12%Accidental Overdose
2%Dermatitis Atopic
1%Multiple Fractures
This histogram enumerates side effects from a completed 2021 Phase 4 trial (NCT04033367) in the OLE Period: Dupilumab/Dupilumab ARM group. Side effects include: Accidental Overdose with 12%, Conjunctivitis with 2%, Nasopharyngitis with 2%, Headache with 2%, Dermatitis Atopic with 2%.

Trial Design

1 Treatment Group

Dupilumab Subcutaneous Injection
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Dupilumab · No Placebo Group · Phase 2

Dupilumab Subcutaneous Injection
Experimental Group · 1 Intervention: Dupilumab · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: assessed at screening, weeks 0, 4, 8, 12, 16, 20, 24

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
777 Previous Clinical Trials
844,360 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
548 Previous Clinical Trials
199,923 Total Patients Enrolled
2 Trials studying Keloid
174 Patients Enrolled for Keloid
Martina Porter, MDPrincipal InvestigatorBeth Israel Deaconess Medical Center
1 Previous Clinical Trials
21 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Before participating in a study, subjects must be able to understand and communicate with the investigator, comply with the requirements of the study, and give written, signed, and dated consent.
People between the ages of 18 and 65 who are starting dupilumab.
to be compliant In order to be compliant, a subject must have either one keloid with a length of ≥ 2 cm or at least two keloids with a width of ≥ 0.4 cm (length) x 0.4 cm (width).

Who else is applying?

What state do they live in?
How old are they?
18 - 6550.0%
What site did they apply to?
Beth Israel Deaconess Medical Center100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria50.0%
Met criteria50.0%